Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 12/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463144 | 0.93 | AVPR2 (0.55) | AVPR2AVPR1AMAPTTP53HTT | |
| SCHEMBL4499296 | 0.91 | AVPR2 (0.55) | AVPR2AVPR1AMAPTTP53HTT | |
| SCHEMBL8233181 | 0.86 | AVPR2 (0.57) | AVPR2AVPR1AMAPTTP53LMNA | |
| SCHEMBL4513387 | 0.84 | AVPR2 (0.57) | AVPR2AVPR1AMAPTTP53HTT | |
| SCHEMBL8232872 | 0.84 | AVPR2 (0.47) | AVPR2AVPR1AMAPTTP53USP2 | |
| SCHEMBL388488 | 0.83 | SCN9A (0.37) | AVPR2AVPR1AMAPTTP53USP2 | |
| SCHEMBL8232662 | 0.83 | AVPR2 (0.46) | AVPR2AVPR1AMAPTTP53USP2 | |
| SCHEMBL12057144 | 0.83 | AVPR2 (0.53) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL718664 | 0.83 | AVPR2 (0.50) | AVPR2AVPR1AMAPTTP53HTT | |
| SCHEMBL718665 | 0.83 | AVPR2 (0.50) | AVPR2AVPR1AMAPTTP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408754-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY | BAYER IP GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| EP-2408754-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY | BAYER IP GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| CN-102369190-A | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | BAYER SCHERING PHARMA AG | 2012-03-07 | — | — | CN | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | AVPR2, AVPR1B, AVPR1A | AVPR2 1/4885AVPR1A 3/4885MAPT 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.